Loading...
•
Sep 30, 2024
Aquestive Q3 2024 Earnings Report
Reported financial results for the third quarter and provided a business update.
Key Takeaways
Aquestive Therapeutics reported a 4% increase in total revenues to $13.5 million for the third quarter of 2024, driven by increases in license and royalty revenue, offset by decreases in manufacture and supply revenue. The company is advancing its key product candidates, Anaphylm and AQST-108, with pre-NDA and pre-IND meetings scheduled for the fourth quarter of 2024, respectively. Aquestive finished the quarter with approximately $78 million in cash and reaffirms its cash runway into 2026.
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024
AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024
Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channels
Finished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026
Revenue by Segment
Forward Guidance
Aquestive expects total revenue between $57 million and $60 million and a non-GAAP adjusted EBITDA loss between $20 million and $23 million for the full year 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...